Undervalued Small-Cap Healthcare Stocks on NAS April 2025

April 07, 2025

Healthcare Sector

The healthcare sector includes companies in biotechnology, pharmaceuticals, hospitals, home and long-term care. It also includes related medical equipment manufacturers and suppliers.

NASDAQ

The National Association of Securities Dealers Automated Quotations (Nasdaq) located in New York City, is the most active stock exchange by volume in the United States.

Our Valuation

A stock is considered undervalued if it trades at a discount to our valuation. To determine a stock’s intrinsic value, we developed an algorithm that uses 6 valuation models to determine the value of a company.* To learn more about stockcalc’s valuation methods, click here.

Undervalued Healthcare stocks

Stocks in this category are held primarily for potential income and capital appreciation.

For an in-depth look at the fundamentals and valuation of each company, try the stockcalc platform free for 30 days.

SymbolNameClose Price ($)Valuation ($)Difference (%)Average Vol (30D)Market Cap ($M)Yield (%)P/E Ratio
AAPG Ascentage Pharma Group - - 0.00 - 0 0.00 0.0
AARD Aardvark Therapeutics - - 0.00 - 0 0.00 0.0
ABCL AbCellera Biologics - - 0.00 - 0 0.00 0.0
ABEO Abeona Therapeutics - - 0.00 - 0 0.00 0.0
ABOS Acumen Pharmaceuticals - - 0.00 - 0 0.00 0.0
ABP Abpro Hldgs - - 0.00 - 0 0.00 0.0
ABSI Absci - - 0.00 - 0 0.00 0.0
ABUS Arbutus Biopharma - - 0.00 - 0 0.00 0.0
ABVC ABVC BioPharma - - 0.00 - 0 0.00 0.0
ABVX Abivax - - 0.00 - 0 0.00 0.0
All data provided as at market close April 06, 2025.

Company Details

Ascentage Pharma Group

AAPG:NAS

Close Price

-

Our Valuation

-

% Difference

0.00

Market Cap ($M)

0

P/E Ratio

0.0

Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The company's geographical segments include the United States and Mainland China.

Access the stockcalc valuation


Aardvark Therapeutics

AARD:NAS

Close Price

-

Our Valuation

-

% Difference

0.00

Market Cap ($M)

0

P/E Ratio

0.0

Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions.

Access the stockcalc valuation


AbCellera Biologics

ABCL:NAS

Close Price

-

Our Valuation

-

% Difference

0.00

Market Cap ($M)

0

P/E Ratio

0.0

AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success.

Access the stockcalc valuation


Abeona Therapeutics

ABEO:NAS

Close Price

-

Our Valuation

-

% Difference

0.00

Market Cap ($M)

0

P/E Ratio

0.0

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB).

Access the stockcalc valuation


Access our valuation for these companies and 9,000+ more

Try the stockcalc platform free for 30 days

Sign Up

Acumen Pharmaceuticals

ABOS:NAS

Close Price

-

Our Valuation

-

% Difference

0.00

Market Cap ($M)

0

P/E Ratio

0.0

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.

Access the stockcalc valuation


Abpro Hldgs

ABP:NAS

Close Price

-

Our Valuation

-

% Difference

0.00

Market Cap ($M)

0

P/E Ratio

0.0

Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology.

Access the stockcalc valuation


Absci

ABSI:NAS

Close Price

-

Our Valuation

-

% Difference

0.00

Market Cap ($M)

0

P/E Ratio

0.0

Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.

Access the stockcalc valuation


Arbutus Biopharma

ABUS:NAS

Close Price

-

Our Valuation

-

% Difference

0.00

Market Cap ($M)

0

P/E Ratio

0.0

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101.

Access the stockcalc valuation


ABVC BioPharma

ABVC:NAS

Close Price

-

Our Valuation

-

% Difference

0.00

Market Cap ($M)

0

P/E Ratio

0.0

ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. For its drug products, it is focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm is specialized in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.

Access the stockcalc valuation


Abivax

ABVX:NAS

Close Price

-

Our Valuation

-

% Difference

0.00

Market Cap ($M)

0

P/E Ratio

0.0

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis.

Access the stockcalc valuation


Access thousands of valuation reports

Try the stockcalc platform for 30 days for unlimited access to our valuation reports

Sign Up
Ascentage Pharma Group and Aardvark Therapeutics are the most undervalued Small-Cap Healthcare stocks on the NAS. See the full list on the blog: https://www.stockcalc.com/Blog/undervalued-small-cap-healthcare-stocks-nas-april-2025
Ascentage Pharma Group $AAPG and Aardvark Therapeutics $AARD are the most undervalued Healthcare stocks on the #NAS. See the full list: https://www.stockcalc.com/Blog/undervalued-small-cap-healthcare-stocks-nas-april-2025
Ascentage Pharma Group and Aardvark Therapeutics are the most undervalued Small-Cap Healthcare stocks on the NAS. See the full list on the blog: https://www.stockcalc.com/Blog/undervalued-small-cap-healthcare-stocks-nas-april-2025

Copyright © 2016- Patchell Brook Equity Analytics Inc. All rights reserved.

Risk Disclosure: Equities trading and trading of all markets, exchanges and instruments contains substantial risk and is not for every investor. An investor could potentially lose all or more than the initial investment. Risk capital is money that can be lost without jeopardizing ones’ financial security or life style. Only risk capital should be used for trading and only those with sufficient risk capital should consider trading. Past performance is not necessarily indicative of future results. View full risk information here.